Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

Chemotherapy is the backbone of small-cell lung cancer therapy. However, optimal drug combinations and schedules remain to be defined and there is hitherto no world-wide accepted standard regimen. Cisplatin, an alkylating agent with high putative toxicity is currently widely used although its effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Pujol, J-L, Carestia, Daurès, J-P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374541/
https://www.ncbi.nlm.nih.gov/pubmed/10883661
http://dx.doi.org/10.1054/bjoc.2000.1164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374541/
https://www.ncbi.nlm.nih.gov/pubmed/10883661
http://dx.doi.org/10.1054/bjoc.2000.1164

Ejemplares similares